{"id":30935,"date":"2025-03-31T13:12:27","date_gmt":"2025-03-31T05:12:27","guid":{"rendered":"https:\/\/flcube.com\/?p=30935"},"modified":"2025-03-31T13:12:29","modified_gmt":"2025-03-31T05:12:29","slug":"brii-biosciences-presents-elebsiran-phase-ii-data-at-apasl-2025-meeting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30935","title":{"rendered":"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting"},"content":{"rendered":"\n<p>China-based Brii Biosciences Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2137:HKG\">HKG: 2137<\/a>) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being evaluated for its contribution to treating chronic hepatitis B virus (HBV) infection.<\/p>\n\n\n\n<p><strong>Study Design and Cohorts<\/strong><br>The multi-center, open Phase II study includes Cohorts 1-3, assessing elebsiran in combination with pegylated interferon alpha (PEG-IFN\u03b1) in participants with chronic HBV and baseline hepatitis B surface antigen (HBsAg) levels of 100-3,000 IU\/mL. Cohort 4 enrolled participants who previously completed 9 doses of BRII-179, a therapeutic vaccine, in combination with elebsiran, and received elebsiran and PEG-IFN\u03b1 combination treatment.<\/p>\n\n\n\n<p><strong>Cohort 4 Insights<\/strong><br>Cohort 4&#8217;s design was informed by previous studies indicating that many chronic HBV patients fail to generate a sufficient immune response after multiple doses of BRII-179, making sustainable functional cure unlikely without additional support.<\/p>\n\n\n\n<p><strong>Emerging Data and Implications<\/strong><br>Data from Cohort 4 showed that participants with BRII-179-induced anti-HBs response achieved a significantly higher rate of HBsAg seroclearance. At Week 24, 55.6% of BRII-179 responders achieved HBsAg seroclearance, compared to 10.0% of non-responders. These results suggest BRII-179 can predict patient response to curative therapies.<\/p>\n\n\n\n<p><strong>Elebsiran Mechanism<\/strong><br>Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade HBV RNA transcripts and limit HBsAg production. Brii Biosciences licensed elebsiran from Vir Biotechnology, Inc. (Nasdaq: VIR) in 2020, gaining exclusive rights to develop and commercialize it in Greater China. It is being tested in combination with monoclonal antibody BRII-877 (tobevibart) or immunotherapy BRII-179 for HBV infection.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":30936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,449,17,1219,64,89],"class_list":["post-30935","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-brii-biosciences","tag-clinical-trial-results","tag-hkg-2137","tag-rnai-aso","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being evaluated for its contribution to treating chronic hepatitis B virus (HBV) infection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30935\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting\" \/>\n<meta property=\"og:description\" content=\"China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being evaluated for its contribution to treating chronic hepatitis B virus (HBV) infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30935\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-31T05:12:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-31T05:12:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/3105-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting\",\"datePublished\":\"2025-03-31T05:12:27+00:00\",\"dateModified\":\"2025-03-31T05:12:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935\"},\"wordCount\":277,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/3105-png.webp\",\"keywords\":[\"Academic conference\",\"Brii Biosciences\",\"Clinical trial results\",\"HKG: 2137\",\"RNAi \\\/ ASO\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30935#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30935\",\"name\":\"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/3105-png.webp\",\"datePublished\":\"2025-03-31T05:12:27+00:00\",\"dateModified\":\"2025-03-31T05:12:29+00:00\",\"description\":\"China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being evaluated for its contribution to treating chronic hepatitis B virus (HBV) infection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30935\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/3105-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/3105-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30935#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being evaluated for its contribution to treating chronic hepatitis B virus (HBV) infection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30935","og_locale":"en_US","og_type":"article","og_title":"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting","og_description":"China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being evaluated for its contribution to treating chronic hepatitis B virus (HBV) infection.","og_url":"https:\/\/flcube.com\/?p=30935","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-31T05:12:27+00:00","article_modified_time":"2025-03-31T05:12:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/3105-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30935#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30935"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting","datePublished":"2025-03-31T05:12:27+00:00","dateModified":"2025-03-31T05:12:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30935"},"wordCount":277,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30935#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/3105-png.webp","keywords":["Academic conference","Brii Biosciences","Clinical trial results","HKG: 2137","RNAi \/ ASO","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30935#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30935","url":"https:\/\/flcube.com\/?p=30935","name":"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30935#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30935#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/3105-png.webp","datePublished":"2025-03-31T05:12:27+00:00","dateModified":"2025-03-31T05:12:29+00:00","description":"China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being evaluated for its contribution to treating chronic hepatitis B virus (HBV) infection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30935#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30935"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30935#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/3105-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/3105-png.webp","width":1080,"height":608,"caption":"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30935#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/3105-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30935"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30935\/revisions"}],"predecessor-version":[{"id":30937,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30935\/revisions\/30937"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30936"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}